A third anti-SARS-CoV-2 mRNA dose does not overcome the pejorative impact of anti-CD20 therapy and/or low immunoglobulin levels in patients with lymphoma or chronic lymphocytic leukemia

Haematologica. 2022 Jun 1;107(6):1454-1459. doi: 10.3324/haematol.2021.280026.
No abstract available

MeSH terms

  • Antigens, CD20 / genetics
  • COVID-19*
  • Humans
  • Immunoglobulins
  • Leukemia, Lymphocytic, Chronic, B-Cell* / drug therapy
  • Leukemia, Lymphocytic, Chronic, B-Cell* / genetics
  • Leukemia, Lymphocytic, Chronic, B-Cell* / pathology
  • Lymphoma* / drug therapy
  • RNA, Messenger
  • Rituximab / therapeutic use

Substances

  • Antigens, CD20
  • Immunoglobulins
  • RNA, Messenger
  • Rituximab